Overview of Dolospam (ANTISPASMODIC)

Property	Description
Active ingredient	Atropine Sulfate, Papaverine
Form	Solution for injection
Pharmacological class	Antispasmodic, Smooth Muscle Relaxant
Common use	Relief of visceral spasms
Origin	Combined (Synthetic-derived Atropine, Natural-derived Papaverine)

Dolospam is defined as a specific combination pharmaceutical preparation that belongs to the ANTISPASMODIC pharmacological class, used fundamentally as a smooth muscle relaxant. Its core purpose, clinically recognized for its efficacy, is to counteract the excessive and painful involuntary contractions, or visceral spasms, that occur in the walls of internal hollow organs. The formulation is presented as a sterile solution for injection, suitable for parenteral administration, positioning it as a medicine used when rapid onset of action is required.

The active composition features two distinct alkaloid ingredients: Atropine Sulfate and Papaverine. Atropine Sulfate functions primarily as an anticholinergic agent, working to block specific nerve signals that cause muscular contraction. The other component, Papaverine, is a benzylisoquinoline alkaloid that acts as a direct musculotropic agent, causing the muscle fibers themselves to relax.

The primary therapeutic advantage of Dolospam lies in this dual mechanism of effect, providing a broader and often more rapid smooth muscle relaxation than a single agent. Papaverine acts on various smooth muscle groups, including those in the gastrointestinal tract and blood vessels, functioning as a direct-acting smooth muscle relaxant. This synergy results in comprehensive relief from muscular hyperactivity, making it a recognized choice for managing acute spasmodic conditions.

Regulatory References

direct-acting smooth muscle relaxant

What side effects are possible with Dolospam (ANTISPASMODIC)?

Possible Side Effects and Safety Information

The safety profile of Dolospam, a combination of Atropine Sulfate and Papaverine, is defined by regulatory agencies across multiple System-Organ Classes, reflecting the drug's systemic effects. Officially documented adverse reactions range from common effects related to the anticholinergic action of Atropine to less frequent but more serious risks.

Commonly Occurring Adverse Reactions

Adverse reactions that are commonly occurring with chronic administration of therapeutic doses include dryness of the mouth (xerostomia), blurred vision, photophobia, and tachycardia (increased heart rate). Other frequently documented effects are constipation, headache, and dizziness.

Serious Adverse Reactions and Population Constraints

The regulatory safety documentation lists several serious adverse reactions. These include the potential for anaphylaxis, precipitation of acute glaucoma, and the risk of worsening pre-existing Ischemic Heart Disease due to induced tachycardia. Papaverine's profile includes infrequently reported hepatitis, with a rare progression to cirrhosis. Furthermore, the label specifies contraindications, notably for existing Glaucoma, Tachycardia, and Complete Atrioventricular (AV) Heart Block.

Population-specific safety considerations are mandated for older adults, who may experience increased difficulty in micturition (urinary issues) and mental confusion. Patients with Prostatic Hypertrophy carry a documented risk of complete urinary retention. Safety is also conditioned by dose-related patterns, where bradycardia may follow low systemic doses of Atropine, while tachycardia occurs after higher doses.

Overdose and Emergency Response

Overdose Map: Overdose and when to seek help — Official Regulatory Information for Dolospam (ANTISPASMODIC)

Overdose Scope

Feature	Official Regulatory Statement
Documented Overdose Presentations	Exaggerated pharmacological effects leading to a severe anticholinergic syndrome. Presentations include CNS excitation followed by depression, severe cardiovascular instability, and respiratory distress.
Physiological Systems Affected	Central Nervous System, Cardiovascular System, Autonomic Nervous System (specifically parasympathetic blockade).
Dose-Related Factors	Overdose symptoms are typically seen with doses significantly exceeding the maximum therapeutic daily dose or following inadvertent ingestion of large amounts.
Emergency-Response Statements	Immediate gastric decontamination (e.g., activated charcoal) is required. Maintain vital functions, provide supportive and symptomatic care. Consider a specific antidote (e.g., physostigmine) for life-threatening central anticholinergic effects.
When Immediate Medical Help is Required	Urgent medical attention is necessary in all cases of suspected overdose, regardless of initial symptoms. Contact a poison control center or emergency services immediately.

Resulting Overdose Structure

Official Overdose Statements:

Symptoms of Overdose: Manifestations include confusion, agitation, hallucinations, psychosis, coma; tachycardia, hypotension, arrhythmias; and peripheral signs like mydriasis, dry mouth, and urinary retention.
Emergency Procedure: Seek immediate medical help. Management is primarily supportive. Procedures may include gastric decontamination to reduce absorption.

Connection to the overall overdose profile: The regulatory documents define the overdose profile of Dolospam as an acute and potentially severe anticholinergic syndrome, impacting critical central nervous and cardiovascular functions. The official statements mandate that a suspected overdose requires urgent medical attention to manage life-threatening symptoms, outlining specific procedural instructions for decontamination and emphasizing supportive care, with the potential use of an antidote for severe central effects.

Therapeutic Uses of Dolospam (ANTISPASMODIC)

Quick Facts

Targeted Symptom Relief: Assists in addressing discomfort from involuntary smooth muscle contractions.
Primary Application: Used to manage symptoms associated with Irritable Bowel Syndrome (IBS).
Common Contexts: Utilized to support the relief of abdominal pain and cramping.

Dolospam is a prescription medication utilized in therapeutic regimens focused on managing symptoms resulting from the involuntary contraction of smooth muscles in certain organ systems, primarily the gastrointestinal tract. As an antispasmodic, its approved use is to provide relief from concerns such as abdominal discomfort, painful spasms, and cramping.

It is often incorporated into a comprehensive plan for individuals who experience the constellation of symptoms associated with Irritable Bowel Syndrome (IBS). In this context, the medication offers symptomatic support, particularly for abdominal pain and cramping believed to be related to heightened intestinal muscle activity.

The therapeutic intent is to modulate the severity and frequency of these involuntary muscle contractions. Furthermore, Dolospam may be considered in other contexts where smooth muscle spasm relief is an objective, consistent with medical guidance. Patients are advised to consult their healthcare provider for a thorough assessment to determine if this treatment option is appropriate for their specific health needs.

Eligibility and Restrictions for Use

Eligibility Map: Who can and cannot use Dolospam (ANTISPASMODIC) — official regulatory information

Official regulatory documents define a patient's eligibility for antispasmodic medications based on specific contraindicated conditions and population-related restrictions.

Eligibility scope

Classification	Rule	Status
Contraindicated Populations	Patients with obstructive conditions of the gastrointestinal or urinary tract	Must Not Use
Use Limitation	Patients with hepatic impairment or severe kidney disease	Restricted Use
Age Restriction	Infants and young children	Not Recommended/Safety Not Established

Eligibility Classifications (High-Level)

Populations for whom use is contraindicated: Contraindications commonly include conditions that could be worsened by smooth muscle relaxation, such as paralytic ileus, pyloric stenosis, myasthenia gravis, and urinary retention (e.g., due to prostatic enlargement).
Age-related eligibility rules: Older adults typically require caution and often a reduced dosage due to increased susceptibility to anticholinergic effects. Use in infants and young children is frequently not recommended or specifically contraindicated by regulators due to insufficient safety data or higher risk of adverse reactions.
Condition-specific eligibility rules: Patients with conditions that increase ocular pressure, such as certain types of glaucoma (e.g., narrow-angle glaucoma), are excluded from use. Similarly, caution is mandated for patients with cardiac conditions (e.g., acute myocardial infarction, hypertension) or significant hepatic impairment.

Connection to the Overall Eligibility Profile

Official regulatory documents define who can and cannot use this medicine primarily through absolute contraindications related to obstructive disorders and conditions involving muscle weakness. The profile is further structured by mandating conditional use or caution for vulnerable groups, such as the elderly and those with pre-existing organ dysfunction (liver/kidney) or pre-existing cardiac or ocular disease, reflecting the need to mitigate specific risks documented during development.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Official regulatory information describes specific interaction patterns for Dolospam (Atropine Sulfate and Papaverine) based on additive pharmacological effects and pharmacokinetic alterations.

Pharmacodynamic Interactions

Co-administration with agents possessing anticholinergic activity (such as tricyclic antidepressants, MAOIs, and certain antihistamines) results in enhanced peripheral and central anticholinergic effects, as documented in regulatory sources.

Simultaneous use with other potent CNS depressants (including alcohol, barbiturates, and tranquilizers) may lead to the potentiation of sedation.

Cardiovascular Interactions: The label includes restrictions for co-administration with drugs classified as having a high risk of QTc prolongation (e.g., Pimozide, Dronedarone), which may result in an additive cardiac risk. Papaverine may also increase the hypotensive effects of certain antihypertensive drugs.

Pharmacokinetic and Therapeutic Interference

The anticholinergic component's action on gastrointestinal motility establishes a pharmacokinetic interaction that can reduce the absorption and systemic exposure of other orally administered medicines, such as Mexiletine. This mechanism requires consideration for co-administered oral drugs.

Separation of administration is required for sublingual preparations (e.g., Nitrates), as the documented side effect of dry mouth may impede their dissolution and reduce effectiveness.

Finally, Papaverine may officially interfere with the therapeutic outcomes of Levodopa, potentially leading to a loss of antiparkinsonian effect.

Mechanism of Action

Dolospam, a direct smooth muscle relaxant, exerts its primary action by targeting musculotropic components within the gastrointestinal tract. The molecular mechanism involves the compound acting as an inhibitor of specific phosphodiesterase (PDE) isoenzymes, predominantly PDE4.

Inhibition of PDE4 reduces the enzymatic hydrolysis of intracellular cyclic adenosine monophosphate (cAMP). This results in an elevated cytoplasmic concentration of cAMP. The resulting downstream cascade involves the activation of protein kinase A (PKA), which promotes the phosphorylation of target proteins essential for muscle contraction, including myosin light chain kinase (MLCK).

Phosphorylation of MLCK leads to its inactivation, preventing the phosphorylation of the myosin light chain. Furthermore, the elevated cAMP levels may modulate voltage-dependent calcium channels and calcium-release channels, decreasing the calcium influx necessary for the actin-myosin cross-bridge formation. This intracellular modification results in a sustained decrease in smooth muscle tone and amplitude of contraction within the intestinal and biliary systems, leading to a system-level physiological modulation of hypermotility.

Dosage and Administration Information

How to Use Dolospam (ANTISPASMODIC)

Dolospam is a combination medication administered exclusively via the parenteral route, typically as an Intravenous (IV), Intramuscular (IM), or Subcutaneous (SC) injection. Its use is authorized for the short-term, intermittent management of acute spasmodic events, rather than as a scheduled, chronic therapy. The medication is therefore administered on an as-needed (PRN) basis following the onset of the episode.

Official Administration Guidelines

Instruction Entity	Guideline Details
Route of administration	IV, IM, or SC injection.
Dosing schedule (Adults)	Papaverine component single doses range from 30 mg to 65 mg; Atropine component single doses range from 0.25 mg to 1 mg.
Frequency	Doses may be repeated every 3 to 6 hours as required, but must not exceed the Atropine component's maximum total daily dose of 2 mg.
Age-group rules	Pediatric dosing for the Atropine component is weight-based, calculated at approximately 0.01 mg/kg for the SC or IV route.

Procedural Conditions

Administration involves specific steps to ensure safe delivery and efficacy. Prior to administration, the solution must be visually inspected for any particles or discoloration. When delivered intravenously, the injection must be performed slowly over a period of 1 to 2 minutes to meet standard procedural requirements. Furthermore, the solution is chemically incompatible with and must not be mixed with certain intravenous fluids, such as Lactated Ringer’s Injection, to prevent precipitation of the Papaverine component.

The collected instructions establish a standardized protocol that requires parenteral delivery and defines precise numerical ranges, administration rate constraints, and procedural steps for the use of this acute antispasmodic.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Dolospam (ANTISPASMODIC)

Evidence for Use in Visceral Spasms

Research for this medicine was studied for general visceral spasms. This foundational research includes controlled trials and studies applied in research contexts involving fluctuating or unstable symptoms. Research examined the medicine in contexts involving conditions associated with acute episodes, with studies primarily focusing on patient-reported outcomes describing perceived discomfort and outcomes related to systemic or functional imbalance. Research in these contexts was often applied in studies examining short-term or episodic symptom patterns.

Findings from these initial studies described patterns observed in the timeframes of acute changes and patterns related to episodic or acute changes in muscular activity following administration. Research highlights changes measured during the study period, including measurements of patient-reported outcomes describing perceived discomfort, and how excessive involuntary contractions were observed in the observed populations during the study period. This evidence contributes to the broader evidence landscape regarding the therapeutic class.

Evidence for Use in Irritable Bowel Syndrome (IBS) Symptoms

The evidence base for its application in conditions characterized by fluctuating or episodic manifestations, such as Irritable Bowel Syndrome (IBS), is largely drawn from earlier controlled clinical trials and subsequent systematic reviews of the drug class. Studies primarily evaluated outcomes related to physical discomfort and outcomes capturing phases of heightened symptom activity in adult patients diagnosed with IBS. Reports described measurements of overall symptomatic response, and research provides insight into short-term changes monitored during the study period.

What Is Still Uncertain About Dolospam (ANTISPASMODIC)

Despite the foundational research, evidence for certain groups remains insufficient. Few data are available for specific groups such as pediatric patients or older adults with complex health profiles. Comparative evidence is lacking for its performance directly against many newer antispasmodic agents. The limited information for long-term outcomes means that understanding the effects beyond the acute or short-term treatment period is not fully established, and this area remains a topic where research is ongoing. Results apply only to the populations studied due to limitations like modest sample sizes.

Frequently Asked Questions (FAQ)

Common questions about Dolospam (ANTISPASMODIC) (FAQ)

Q: How quickly should I expect to feel relief after taking Dolospam?

A: Since Dolospam is administered by injection (parenterally) for acute episodes, the onset of action is generally rapid. Official product information for the Atropine component indicates that relief can begin within about one minute following intravenous administration.

Q: Can you take Dolospam with common pain relievers like paracetamol or ibuprofen?

A: Regulatory information advises caution when combining Dolospam with other medicines that affect the central nervous system (CNS), which could increase sedation. Interactions with common non-opioid pain relievers like paracetamol or ibuprofen are not explicitly restricted, but it is important that healthcare professionals are informed of all medications being taken prior to administration.

Q: Are there any food or drinks I should avoid while using Dolospam?

A: According to official product information, alcohol should be avoided because simultaneous use with CNS depressants may lead to potentiation of sedation. The medication's regulatory label does not list any specific food items that must be restricted.

Q: How long can a person safely take Dolospam continuously?

A: Dolospam is authorized for the short-term, intermittent management of acute spasms, not as a scheduled, long-term therapy. Regulatory guidelines restrict the maximum total daily dose of the Atropine component, reinforcing its purpose for temporary or as-needed use during acute episodes.

Q: Is it okay to drink a small amount of alcohol while taking Dolospam?

A: The official product information warns that simultaneous use of alcohol with this medicine may lead to an increase in sedative effects. Regulatory documents do not define a 'safe' small amount of alcohol that can be consumed without risk.

Q: Does taking Dolospam with food change how well it is absorbed?

A: No, because Dolospam is administered exclusively by injection (parenteral route), its absorption into the body is not affected by food intake, unlike oral medications.

Q: Can Dolospam make you feel drowsy or sleepy?

A: Yes, official safety information for the Papaverine component of Dolospam lists drowsiness as a common side effect. Due to this potential effect, activities requiring full alertness, such as driving or operating machinery, should be avoided until the drug's effect is known.

Q: Is Dolospam a type of narcotic or painkiller?

A: No, Dolospam is classified by regulatory bodies as an Antispasmodic and a Smooth Muscle Relaxant. Its primary function is to stop excessive muscle contractions (spasms) in hollow organs; it is not classified as a narcotic or analgesic (painkiller) in its official labeling.

Q: Do studies show that Dolospam is effective for IBS symptoms?

A: Studies and official information indicate that early controlled clinical trials and systematic reviews of the drug class suggest the medication can be effective for managing acute episodes of symptoms associated with Irritable Bowel Syndrome (IBS).

Q: Is Dolospam considered an over-the-counter medicine in some countries?

A: No, in major regulatory jurisdictions, Dolospam is uniformly classified as a prescription-only medicine (Rx-only). This is due to its composition and the requirement that it must be administered by injection.

Q: Can Dolospam affect the color or consistency of urine or stool?

A: The safety profile for the Papaverine component includes infrequently reported hepatitis (liver issues). Infrequently reported signs of liver issues, which are associated with the Papaverine component, can include dark urine or stools that appear pale or clay-colored.

Q: Are there withdrawal symptoms if I stop taking Dolospam suddenly?

A: While intended for short-term use, the product information indicates that tolerance and physical dependence can develop with prolonged use of excessive dosages. In these specific cases, abrupt cessation may cause withdrawal symptoms.

Q: Can children or teenagers use Dolospam for stomach cramps?

A: Official information states that use in infants and young children is generally not recommended or that safety has not been fully established in those groups. Although pediatric dosing is provided for the Atropine component, data on general safety and use in teenagers may be limited or restricted.

Q: Does the effectiveness of Dolospam decrease over time?

A: Yes, regulatory documents note that tolerance to the Papaverine component may occur, particularly during long-term use. This effect may reduce the medication's effectiveness over time.

Q: What are the signs of a serious allergic reaction to Dolospam?

A: Serious adverse reactions listed in regulatory documents include the potential for anaphylaxis. Signs can include hives, difficulty breathing, swelling of the face, lips, tongue, or throat, or unusual hoarseness.

Q: How long does Dolospam stay in your system after the last dose?

A: The time it takes for the body to eliminate half of the drug (elimination half-life) is approximately 2 hours for the Atropine component and between 1.5 and 2 hours for the Papaverine component.

Q: Is there a generic version of Dolospam available?

A: The active ingredients in this combination medicine, Atropine Sulfate and Papaverine, are available as single-ingredient generic injectable solutions.

Q: Why is Dolospam sometimes given by injection in a hospital setting?

A: Dolospam is provided as a sterile solution for injection (IV, IM, or SC) and is used for acute spasmodic events. This parenteral route is chosen because it allows for a very rapid onset of action, which is required when quickly addressing severe or acute spasms, typically performed under the supervision of a healthcare professional.

Q: Can Dolospam affect your ability to drive or operate machinery?

A: The official label advises that patients should not drive or operate machinery until they are aware of how the medication affects them. Side effects such as dizziness and blurred vision may potentially impair the ability to perform these tasks.

Q: Are there any specific warning signs of an overdose of Dolospam?

A: Regulatory documents list several signs associated with an overdose, particularly from the Atropine component. These can include a rapid heart rate (palpitation), dilated pupils, difficulty in swallowing, hot dry skin, thirst, dizziness, restlessness, tremor, fatigue, and delirium.

Q: Can Dolospam cause feelings of restlessness or agitation?

A: Yes, official product information indicates that feelings of restlessness and agitation are listed as potential effects that may occur following excessive dosing or in cases of overdose.

How should Dolospam (ANTISPASMODIC) be stored and disposed of?

How to Store and Dispose of Dolospam (ANTISPASMODIC)

Official regulatory guidelines define specific conditions for storing and disposing of this sterile solution to maintain product stability and safety.

Storage Requirements

Condition	Requirement
Temperature	Store at Controlled Room Temperature, 20 C to 25 C (68 F to 77 F). Do Not Freeze.
Protection	The vials must be Protected from Light and excessive moisture; retain the product in its outer carton until use.
Stability	Any unused portion from multi-dose containers must be discarded within 24 hours of the initial puncture. Single-dose vials must be used once and discarded.
Safety	The medication must be kept out of the sight and reach of children.

Disposal Instructions

Unused or expired Dolospam must be disposed of according to local pharmaceutical waste regulations. The preferred method is utilization of a drug take-back program. The product must not be emptied into drains or sewers to prevent environmental release.

Dolospam (ANTISPASMODIC)